Dr Chris Luke, Consultant in Emergency Medicine, on Whooping Cough And Immunisation, RTÉ Today Show. – Video

Posted on by


Dr Chris Luke, Consultant in Emergency Medicine, on Whooping Cough And Immunisation, RT Today Show.
Dr Chris Luke, Consultant in Emergency Medicine, on Whooping Cough And Immunisation, RT Today Show.

By: IAEMofficial

View original post here:

Dr Chris Luke, Consultant in Emergency Medicine, on Whooping Cough And Immunisation, RTÉ Today Show. - Video

1st Choice Acupuncture

Posted on by


1st Choice Acupuncture Integrative Medicine, Bellevue, WA (425) 392-8881 1stchoiceacupuncture.com
Welcome to 1st Choice Acupuncture Integrative Medicine! The following presentation will walk you through all the important aspects of our clinic in a nutsh...

By: David Lin

Read this article:

1st Choice Acupuncture

Reproductive Medicine Associates of New Jersey Receives ACOG Prize for Paper on SET and CCS, a Pioneering IVF Process

Posted on by

NEW ORLEANS, May 8, 2013 /PRNewswire/ --Eric J. Forman, M.D., Reproductive Endocrinologist and Infertility Fellow at Robert Wood Johnson Medical School/Reproductive Medicine Associates of New Jersey (RMANJ), today presented research demonstrating that screening embryos for chromosomal abnormalities, then transferring just one chromosomally normal (euploid) embryo during IVF offers delivery rates that are equivalent to the more standard procedure of transferring two embryos with no screening, while also resulting in fewer incidents of twins and thus healthier obstetrical and pediatric outcomes. The paper was awarded third prize in the category of current clinical and basic investigation by the Committee on Scientific Program Awards at the American College of Obstetricians and Gynecologists 61st Annual Clinical Meeting in New Orleans, May 4-8, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120402/NY80340LOGO)

"With infertility treatments generating 18 percent of all twin deliveries in the U.S., reducing the burden of care that these deliveries often create has been a pursuit of reproductive endocrinologists, ob/gyns, and managed care providers for some time. But a safe and effective pathway to singleton deliveries in IVF has been elusive until now," said Forman. "Single embryo transfer with comprehensive chromosome screening has the potential to be revolutionary in the world of IVF, allowing patients to maintain excellent delivery rates while not taking on the treatment-related risk of multiples. And for ob/gyns, it means fewer high-risk pregnancies handed off to them, reducing the healthcare burden across the spectrum."

According to Forman, less than ten percent of IVF patients opt for SET, choosing instead to transfer two or more embryos to achieve the best chance at pregnancy, despite the inherent risks associated with multiple births. But as more patients learn about the equivalent success rates of SET when paired with comprehensive chromosomal screening, those numbers are likely to increase.

Richard T. Scott, Jr., M.D., FACOG, HCLD, and co-founder of RMANJ, says that by integrating knowledge of the entire IVF process with advanced technologies, enhanced embryo selection is making successful SET outcomes broadly achievable.

"Up to this point, double embryo transfer has reliably resulted in higher delivery rates per single fresh cycle than SET, making it the standard of care, despite multiple risk factors," he said. "Today, however the synchronous transfer of a single euploid embryo provides delivery rates of 55 to 65 percent through maternal ages of 42, exceeding national delivery rates." Dr. Scott added, "The Blastocyst Euploid Selective Transfer (BEST) Trial, now in-press, is just one of the many leadership research initiatives RMANJ has undertaken to support both infertility providers and patients. In fact, RMANJ recently submitted 33 abstracts for this year's American Society for Reproductive Medicine annual meeting in Boston, MA."

About the Study

To reach their findings, Forman and his team at RMANJ Basking Ridge randomized 175 women up to age 43 to either have SET with comprehensive chromosome screening for preimplantation aneuploidy assessment, or a double embryo transfer (DET) with no screening. Delivery rates were equivalent (SET 61% vs. DET 65%) with no twins after SET and 53 percent multiples after DET. After the first 49 deliveries (26 SET, 23 DET), patients undergoing euploid SET reported a longer mean gestation (38.7 vs. 37 weeks) and increased newborn birth weight (3422 vs. 2593 grams). Newborns after SET had a lower rate of NICU admission (8% vs. 35%) and spent less total time in the NICU than those after DET (13 days vs. 280 days). There was a trend toward more deliveries prior to 34 weeks after DET (0% vs. 17%). As was reported at Dr. Forman's presentation today, results through the first 100 deliveries demonstrated a three-fold increased risk of preterm delivery after DET compared with euploid SET.

Forman pointed out that the type of chromosomal screening used for the study, which was done on fresh blastocysts, is only available at the few clinics associated with RMANJ, but should become more widely available soon. Studies on the cost implications of the methodology are underway as well.

"Currently, embryo biopsy and comprehensive chromosome screening adds an additional cost to the IVF cycle," he said. "Research is ongoing at RMANJ to determine overall healthcare savings due to the improved obstetrical outcomes when the screening is combined with SET, which could ultimately lower costs across the continuum."

See the rest here:

Reproductive Medicine Associates of New Jersey Receives ACOG Prize for Paper on SET and CCS, a Pioneering IVF Process

MD² Delivers High-Touch Medicine to the Upper East Side

Posted on by

BELLEVUE, Wash.--(BUSINESS WIRE)--

MD International, the founders and definitive providers of concierge medicine, opened their Park Avenue practice on the Upper East Side of Manhattan with Drs. Shari Midoneck and George Ellis. The expanding collection of primary care offices now grants select families access to the most highly sought-after internists and specialists in the most well travelled cities in the United States.

Arguably we have assembled a group of the most distinguished internists in the country, all with long-standing ties to the most sought-after medical institutions in their cities. No other group of internists can offer the level of access across the country that we now provide, said Peter Hoedemaker, MD CEO.

NewYork was a clear choice for the distinguished group of primary care physicians, who care for highly mobile executives (many of whom have multiple homes) in a way that compliments their unique lifestyle.

My patients are people who cherish every aspect of their life: excellence, privacy, devotion and precision. When you really examine it, MD is more in concert with how most of these patients handle other important matters in their lives, whether it is their financial or legal affairs. Yet, nothing is more precious than their health. But with their health, people have accepted a level of service, attention and expertise that is, at best, standard, said Dr. Midoneck.

I am truly honored to now be part of MD, which will give me the time and resources to offer the quality of care I dreamed of in medical school, said Midoneck.Prior to joining MD Park Avenue, Dr. Midoneck had a prominent practice at the Iris Cantor Womens Health Center, where she was respected for her commitment to compassionate, personalized care, and where she cared for some of the communitys most high-profile members. Her partner, Dr. Ellis, equally as cherished, is dual board certified in internal medicine and cardiology.

MD now has offices in New York, Chicago, Dallas, San Francisco, Portland, Bellevue and Seattle; and will open in Menlo Park this summer.All MD physicians care for only 50 families each, which allows them to offer highly personalized care in a private setting. TheMD Park Avenue medical office is located in the heart of the Upper East Side of Manhattan.

About MD

MD International, LLC was founded in Seattle in 1996 and is the definitive provider of concierge medicine. With a collection of primary care offices located in well-travelled cities with major medical institutions, MD offers medicine, tailored to fit the lifestyles of their highly mobile families. Each MD medical office is comprised of two highly regarded internists who care for just 50 families. For more information, visit http://www.md2.com.

See the original post:

MD² Delivers High-Touch Medicine to the Upper East Side

Research and Markets: Personalized Medicine – Scientific and Commercial Aspects – Updated 2013 Report

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/c247cv/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment. Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping. A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2016.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2012-2022.

Profiles of 281 companies involved in developing technologies for personalized medicines, along with 502 collaborations are included in the part II of the report. Finally the bibliography contains over 650 selected publications cited in the report.The report is supplemented by 65 tables and 18 figures.

Key Topics Covered:

Original post:

Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - Updated 2013 Report

Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi

Posted on by

TRENTON, N.J.--(BUSINESS WIRE)--

BioNJ, the trade association for New Jerseys biotechnology industry, is hosting its biggest and most interactive event of the year for companies involved in diagnostics and personalized medicine on June 6, 2013 at Sanofis US headquarters in Bridgewater, NJ.

Expanded this year due to the success of last years inaugural event, the 2013 BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies and emerging innovator companies for a full-day, interactive summit meeting.

We were delighted with the level of interest and participation in last years event, said Debbie Hart, President of BioNJ. So this year we are doing it bigger and better, extending the agenda to a full day and bringing in more first-class speakers from all key constituencies involved with diagnostics and personalized medicine. The BioNJ Diagnostics & Personalized Medicine Innovation Summit has quickly become a must-attend event for anybody interested in this exciting new frontier of medicine, where a lot of New Jersey companies are leading the way.

Part of BioNJs ongoing Diagnostics & Personalized Medicine Initiative, the focus of this summit is to help participants identify opportunities for partnership, funding and growth while updating them on the latest trends, developments and challenges in the evolution and adoption of personalized medicine. All companies and individuals with an interest in diagnostics and personalized medicine are welcome to attend this event. The Summit will include company presentations and opportunities for one-on-one communication and interaction between leading global pharmaceutical and biotechnology companies, emerging diagnostics companies, funding organizations and life sciences company business development professionals.

Keynote speakers at the 2013 Summit include leaders from global life sciences companies as well as the investment community:

G. Steven Burrill Chief Executive Officer, Burrill & Company

Elias Zerhouni, MD President, Global R&D, Sanofi

In addition to keynote speakers, the agenda includes a series of moderated interactive panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Sanofi is fully committed to researching, developing and introducing new products and technologies that deliver on the promise of personalized medicine, and we are excited to be part of this BioNJ event, said Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform at Sanofi, and a Board Member of BioNJ. Better patient outcomes through more precise diagnostics, targeted therapies, increased efficiencies in healthcare delivery, and lower healthcare costs are just a few examples of how personalized medicine could transform healthcare, and our organization is working hard worldwide to contribute to this transformation.

Go here to read the rest:

Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi

Amendment could keep medical school out of Cameron County

Posted on by

The location of the Rio Grande Valleys prospective medical school is now the center of debate.

The conversation now is about the medical school's location.

Cameron County officials have collected 42 pages with 800 signatures in just one day.

The signatures are an effort to keep politics out of dictating the location of the medical school.

"UT has had experience developing medical schools. They've developed 6 of them throughout Texas," Harlingen Mayor Chris Boswell said. Mayor Boswell will head to Austin to present the signatures collected on Wednesday.

Business leaders tell Action 4 News, Senator Juan 'Chuy' Hinojosa may be prepping to amend the bill in efforts to dictate the location of the medical school.

According to the leaders, the move would ensure the new medical school be placed somewhere other than Cameron County.

"Obviously everyone would like to see it in their backyard, the plan for UT is for it to be a reality. The medical school will be a regional school it wont be just in one place," Boswell said.

Mayor Boswell said we do not need the legislature dictating exactly how the medical schools should be laid out.

He said the decision should be left to the doctors, professors and experts who know how to make the decisions.

Here is the original post:

Amendment could keep medical school out of Cameron County

UT unveils plans for medical school

Posted on by

On Wednesday University of Texas officials unveiled plans for the new medical school to be built on campus.

Regents will vote on Thursday on the $334 million construction plan for the school which will be known as the Dell Medical School.

The construction plan includes research, educational and administrative facilities. There will also be a medical office building and a parking garage. Seton Healthcare Family and Central Health would build a new hospital that will be part of the campus.

The medical school campus would be built on land owned by the university north bordered by I-35, 15th Street, Trinity Street and Martin Luther King Boulevard.

According to the plans released by the University of Texas, the plan would disconnect Red River Boulevard between MLK and 15th Street in order to make way for some of the buildings.

The plan would not require the Frank Erwin Center to be relocated. It would, however, require the Penick-Allison Tennis Center be moved.

The Board of Regents Academic Affairs Committee voted Wednesday to recommend the approval of plan for the medical school. The full Board of Regents will vote on the plan Thursday.

"The site plan for this project joins together the best in academic and community resources, and I'm very proud of the Board of Regents' leadership in bringing this medical school to fruition," said Gene Powell, Chairman of the Board of Regents. "We are very excited because establishing a medical school on the campus of UT Austin is one more step to catapulting the university to even greater success, putting it in competition to be the finest public university in the nation."

The University System would finance the project by issuing bonds backed by its state endowment. The Board of Regents has previously pledged an additional $25 million a year to cover operating costs.

The Dell Medical School is expected to open in 2016.

Link:

UT unveils plans for medical school

Dell Medical School in, Erwin Center eventually out

Posted on by

by HEATHER KOVAR / KVUE News and photojournalist CHRISTIAN GARCIA

kvue.com

Posted on May 8, 2013 at 6:14 PM

Updated today at 6:21 PM

AUSTIN--- A unanimous vote was made Wednesday by a committee to recommend approval of the site plan for the Dell Medical School. The University of Texas Board of Regents will vote Thursday.

The initial phase will transform the Waller Creek area from 15th Street to MLK. The Dell Medical School would sit across the Red River from the Frank Erwin Center. Other medical-related buildings are proposed on Waller Creek in the park.

The medical school is expected to open in the summer of 2016. If all goes as planned, Seton would begin construction on a teaching hospital that would be across the street in the parking lot in early 2017.

Larry Speck, a professor in the School of Architecture at UT, presented the master plan to the committee. He says the Frank Erwin Center will coexist with the medical school for a while, however, in six to ten years, the Frank Erwin Center would probably be replaced.

"There would have to be a long-term planning process to eventually phase out the Erwin Center," Speck said.

The 35-year-old Frank Erwin Center is home to UT basketball, the venue for big name concerts and home to quite a bit a history.

Follow this link:

Dell Medical School in, Erwin Center eventually out